HIV molecular immunology database
CRQILGQLQPSLQTG
|
Gag(57-71) | H-2d transgenic mouse epitope |
KQIMKQLQPALQTGT
|
Gag(58-72) | human epitope |
KQIiKQLQPALQTGT
|
Gag(58-72) | subtype-specific non-susceptible form |
crQIlgQLQPALQTGT
|
Gag(58-72) | subtype-specific susceptible form |
KQIigQLQPAiQTGs
|
Gag(58-72) | subtype-specific non-susceptible form |
cqQImeQLQsALkTse
|
Gag(58-72) | subtype-specific non-susceptible form |
LGQLQPSLQTGSEELRSLYN
|
Gag(61-80) | human epitope |
QLQPSLQTGS
|
Gag(63-72) | A*02 human epitope |
QLQPSLQTGSEELR
|
Gag(63-76) | human epitope |
QLQPSLQTGSEELRSLY
|
Gag(63-79) | human epitope |
QTGSEELRSLYNTVATLYCVHQRIE
|
Gag(69-93) | A2 human epitope |
TGTEELRSLYNTVATLY
|
Gag(70-86) | C*14 human epitope |
TGSEELRSLYNTVATLY
|
Gag(70-86) | human epitope |
TGSEELRSLYNTVATLY
|
Gag(70-86) | human epitope |
GSEELRSLY
|
Gag(71-79) | A*01 human epitope |
GSEELRSLY
|
Gag(71-79) | A*01 human epitope |
GSEELkSLY
|
Gag(71-79) | |
GSEELRSLf
|
Gag(71-79) | |
GSEELRSLY
|
Gag(71-79) | A*01 human epitope |
GSEELkSLY
|
Gag(71-79) | escape documented in this paper; observed variant |
GSaELRSLY
|
Gag(71-79) | escape documented in this paper; observed variant |
GSEELRSLf
|
Gag(71-79) | escape documented in this paper; observed variant |
GSEELRSLY
|
Gag(71-79) | A*01 human epitope |
GSEELRSLY
|
Gag(71-79) | A*01 human epitope |
GSEELRSLf
|
Gag(71-79) | escape documented in this paper |
GSEELRSLc
|
Gag(71-79) | inferred escape |
GSEELRSLY
|
Gag(71-79) | A*01 epitope |
GSEELKSLY
|
Gag(71-79) | A*01 human epitope |
GSEELrSLY
|
Gag(71-79) | susceptible form |
GSEELRSLY
|
Gag(71-79) | A*01 human epitope |
GTEELRSLY
|
Gag(71-79) | A*01:01 human epitope |
GTEELRSLY
|
Gag(71-79) | A*01:01 human epitope |
GTEELRSLf
|
Gag(71-79) | diminished HLA binding or increased off-rate; escape documented in this paper |
GSEELRSLY
|
Gag(71-79) | A*01:01 human epitope |
GSEEikSLY
|
Gag(71-79) | diminished HLA binding or increased off-rate; escape documented in this paper |
GSEELRSLY
|
Gag(71-79) | A*01:01 human epitope |
GSEELRSLY
|
Gag(71-79) | A*01:01, B*57 human epitope |
GSEELRSLY
|
Gag(71-79) | A1 human epitope |
GSEELRSLY
|
Gag(71-79) | A1 human epitope |
GSEELRSLY
|
Gag(71-79) | A1 human epitope |
GSEELRSLY
|
Gag(71-79) | A1 epitope |
GSEELRSLY
|
Gag(71-79) | A1 human epitope |
GtEgikSLh
|
Gag(71-79) | observed variant |
GSEELRSLY
|
Gag(71-79) | A1 human epitope |
GSEELRSLY
|
Gag(71-79) | A1 human epitope |
GSEELRSLY
|
Gag(71-79) | A1 human epitope |
GSEELRSLY
|
Gag(71-79) | A1 human epitope |
GSEELRSLY
|
Gag(71-79) | B*07 human epitope |
GSEELRSLY
|
Gag(71-79) | C*14 human epitope |
GSEELRSLY
|
Gag(71-79) | human epitope |
GTEELRSLY
|
Gag(71-79) | human epitope |
GTEELKSLY
|
Gag(71-79) | human epitope |
GSEELRSLYNTVATL
|
Gag(71-85) | human epitope |
GSEELRSLYNTVATL
|
Gag(71-85) | human epitope |
GSEELRSLYNTVATLYCVHQ
|
Gag(71-90) | human epitope |
GSEELRSLYNTVATLYCVHQ
|
Gag(71-90) | human epitope |
EELRSLYNT
|
Gag(73-81) | human epitope |
EELRSLYNTV
|
Gag(73-82) | B*40:06 human epitope |
EELRSLYNTVATLYC
|
Gag(73-87) | A2 human epitope |
EELKSLFNTIAVLWCVHQ
|
Gag(73-90) | human epitope |
EELKSLFNTvAVLWCVHk
|
Gag(73-90) | observed variant |
EELKSLFNTvAVLWCVHQ
|
Gag(73-90) | observed variant |
EELKSLFNTvAVLcCVHQ
|
Gag(73-90) | observed variant |
EELKpLFNTvAVLcCVHQ
|
Gag(73-90) | observed variant |
EELRSLYNTVATLYCVHQ
|
Gag(73-90) | human epitope |
ELRSLYNTV
|
Gag(74-82) | A*24 human epitope |
ELRSLYNTV
|
Gag(74-82) | B*08 human epitope |
ELRSLYNTV
|
Gag(74-82) | B*08 human epitope |
ELRSLYNTV
|
Gag(74-82) | B*08 epitope |
ELKSLYNTV
|
Gag(74-82) | B*08 human epitope |
ELrSLYNTV
|
Gag(74-82) | susceptible form |
ELRSLYNTV
|
Gag(74-82) | B*08 human epitope |
ELRSLYNTi
|
Gag(74-82) | observed variant |
ELRSLfNTi
|
Gag(74-82) | observed variant |
ELRSLcNTi
|
Gag(74-82) | observed variant |
ELRSLYNai
|
Gag(74-82) | observed variant |
ELRSLYNTV
|
Gag(74-82) | B*08 human epitope |
ELRSLYNTV
|
Gag(74-82) | B*08:01 human epitope |
ELRSLYNTV
|
Gag(74-82) | B*08:01 human epitope |
ELRSLYNTV
|
Gag(74-82) | B*08:01 human epitope |
ELRSLYNTV
|
Gag(74-82) | B*40 human epitope |
ELRSLYNTV
|
Gag(74-82) | B*52 human epitope |
ELRSLYNTV
|
Gag(74-82) | B8 human epitope |
ELRSLYNTV
|
Gag(74-82) | B8 human epitope |
ELkSLYNTV
|
Gag(74-82) | observed variant |
ELkSLYNTi
|
Gag(74-82) | inferred escape |
ELkSLfNTV
|
Gag(74-82) | observed variant |
ELKSLyNTV
|
Gag(74-82) | reversion |
ELRSLYNTV
|
Gag(74-82) | B8 human epitope |
ELRSLYNTV
|
Gag(74-82) | B8 human epitope |
ELRSLYNTV
|
Gag(74-82) | B8 human epitope |
ELRSLYNTV
|
Gag(74-82) | B8 human epitope |
ELRSLYNTV
|
Gag(74-82) | B8 human epitope |
ELRSLYNTV
|
Gag(74-82) | B8 epitope |
ELRSLYNTV
|
Gag(74-82) | B8 human epitope |
gikSLhNTV
|
Gag(74-82) | observed variant |
ELKSLFNTI
|
Gag(74-82) | B8 human epitope |
ELRSLYNTV
|
Gag(74-82) | C*06 human epitope |
ELRSLYNTV
|
Gag(74-82) | human epitope |
ELRSLYNTV
|
Gag(74-82) | human epitope |
ELRSLYNTVA
|
Gag(74-83) | A2 human epitope |
ELKSLYNTVATLYCV
|
Gag(74-88) | human epitope |
ELrSLfNTVATLYCV
|
Gag(74-88) | subtype-specific susceptible form |
eELrSLYNTVATLYCV
|
Gag(74-88) | subtype-specific susceptible form |
ELrSLYNTVATLYCV
|
Gag(74-88) | subtype-specific susceptible form |
LKSLfNTVATLYCVH
|
Gag(74-88) | subtype-specific susceptible form |
KSLYNTVCV
|
Gag(76-84) | H-2Db mouse epitope |
RSLYNTVATLY
|
Gag(76-86) | A*02 human epitope |
RSLYNTVATLY
|
Gag(76-86) | A*02:01, A*30:02 human epitope |
RSLYNTiATLY
|
Gag(76-86) | diminished response; escape documented in this paper |
RSLYNTVAvLY
|
Gag(76-86) | diminished response; escape documented in this paper |
RSLYNTiAvLY
|
Gag(76-86) | diminished HLA binding or increased off-rate; diminished response; escape documented in this paper |
RSLfNTiATLY
|
Gag(76-86) | diminished HLA binding or increased off-rate; diminished response; escape documented in this paper |
RSLfNTVATLY
|
Gag(76-86) | diminished HLA binding or increased off-rate; diminished response; escape documented in this paper |
RSLfNTVAvLY
|
Gag(76-86) | diminished HLA binding or increased off-rate; diminished response; escape documented in this paper |
RSLfNTiAvLY
|
Gag(76-86) | diminished HLA binding or increased off-rate; diminished response; escape documented in this paper |
kSLYNTVATLY
|
Gag(76-86) | diminished HLA binding or increased off-rate; diminished response |
kSLYNTVAvLY
|
Gag(76-86) | diminished HLA binding or increased off-rate; diminished response; escape documented in this paper |
kSLYNTiATLY
|
Gag(76-86) | diminished response; escape documented in this paper |
kSLYNTiAvLY
|
Gag(76-86) | diminished HLA binding or increased off-rate; diminished response; escape documented in this paper |
kSLfNTVATLY
|
Gag(76-86) | diminished HLA binding or increased off-rate; diminished response; escape documented in this paper |
kSLfNTiATLY
|
Gag(76-86) | diminished HLA binding or increased off-rate; diminished response; escape documented in this paper |
kSLfNTVAvLY
|
Gag(76-86) | diminished HLA binding or increased off-rate; diminished response; escape documented in this paper |
kSLfNTiAvLY
|
Gag(76-86) | diminished HLA binding or increased off-rate; diminished response; escape documented in this paper |
RSLYNTVATLY
|
Gag(76-86) | A*29 human epitope |
RSLYNTVATLY
|
Gag(76-86) | A*30 human epitope |
RSLfNTVATLY
|
Gag(76-86) | observed variant |
kSLYNTVATLY
|
Gag(76-86) | literature escape |
RSLYNTVAvLY
|
Gag(76-86) | observed variant |
RSLYNTiATLY
|
Gag(76-86) | observed variant |
RSLYNTVvTLY
|
Gag(76-86) | observed variant |
RSLYNTVATLY
|
Gag(76-86) | A*30 human epitope |
RSLYNTVATLY
|
Gag(76-86) | A30 human epitope |
RSLYNTVATLY
|
Gag(76-86) | A30 human epitope |
RSLYNTVATLY
|
Gag(76-86) | A30 human epitope |
RSLYNTVATLY
|
Gag(76-86) | A30 human epitope |
RSLYNTATLY
|
Gag(76-86) | A30 human epitope |
RSLYNTVAVLY
|
Gag(76-86) | A30 human epitope |
RSLYNTVATLY
|
Gag(76-86) | A30 human epitope |
RSLYNTVATLY
|
Gag(76-86) | A30 human epitope |
RSLYNTVATLY
|
Gag(76-86) | A30 epitope |
RSLYNTVATLY
|
Gag(76-86) | A*30:02 human epitope |
RSLYNTVATLY
|
Gag(76-86) | A*30:02 human epitope |
RSLYNTVATLY
|
Gag(76-86) | A*30:02 human epitope |
RLSYNTVATLY
|
Gag(76-86) | A*30:02 human epitope |
RSLYNTVATLY
|
Gag(76-86) | A*30:02 human epitope |
RSLYNTVATLY
|
Gag(76-86) | A*30:02 human, macaque epitope |
RSLYNTVATLc
|
Gag(76-86) | escape documented in this paper |
kSLfNTVATLc
|
Gag(76-86) | escape documented in this paper |
RSLfNTiATLf
|
Gag(76-86) | escape documented in this paper |
RSLYNTVATLY
|
Gag(76-86) | A*30:02 human epitope |
RSLYNTVATLY
|
Gag(76-86) | A*30:02 human epitope |
RSLYNTVATLY
|
Gag(76-86) | A*30:02 human epitope |
RSLYNTVATLY
|
Gag(76-86) | A*30:02 human epitope |
kSLYNTVATLY
|
Gag(76-86) | inferred escape |
kSLYNTVAvLY
|
Gag(76-86) | inferred escape |
RSLYNTVATLY
|
Gag(76-86) | A*30:02 human epitope |
RSLYNTVATLY
|
Gag(76-86) | B57, B58, B63 human epitope |
RSLYNTVATLY
|
Gag(76-86) | B*58 human epitope |
RSLYNTVATLY
|
Gag(76-86) | B*63 human epitope |
RSLYNTVATLY
|
Gag(76-86) | C*03 human epitope |
RSLFNTVATLY
|
Gag(76-86) | human epitope |
RSLyNTVATLY
|
Gag(76-86) | observed variant |
RSLYNTVATLY
|
Gag(76-86) | human epitope |
KSLYNTVVTLWCVHQ
|
Gag(76-90) | human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLFNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLFNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLfNTiAvL
|
Gag(77-85) | escape documented in this paper |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVAvL
|
Gag(77-85) | subtype-specific susceptible form |
SLfNTVATL
|
Gag(77-85) | subtype-specific susceptible form |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLfNTVAvL
|
Gag(77-85) | diminished response |
SLvNTiATL
|
Gag(77-85) | diminished response |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTiATL
|
Gag(77-85) | susceptible form |
SLfNTVATL
|
Gag(77-85) | susceptible form |
SLfNTVAvL
|
Gag(77-85) | susceptible form |
SLfNTiAvL
|
Gag(77-85) | susceptible form |
SLhNTVATL
|
Gag(77-85) | escape documented in this paper; TCR related mutation |
SLYaaaAaL
|
Gag(77-85) | susceptible form |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTIATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVAvL
|
Gag(77-85) | HLA association; processing |
SLfNTVATL
|
Gag(77-85) | HLA association; processing |
SLYNTiATL
|
Gag(77-85) | HLA association; processing |
SLYNTiAvL
|
Gag(77-85) | HLA association; processing |
SLfNTiATL
|
Gag(77-85) | HLA association; processing |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLFNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTiATL
|
Gag(77-85) | susceptible form |
SLfNTiATL
|
Gag(77-85) | diminished response; escape documented in this paper |
SLYNaiATL
|
Gag(77-85) | inferred escape |
SLcNTiATL
|
Gag(77-85) | inferred escape |
SLYNTVATL
|
Gag(77-85) | A*02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVAvL
|
Gag(77-85) | diminished HLA binding or increased off-rate; escape documented in this paper; literature escape; susceptible form |
{k}SLfNTVAvL
|
Gag(77-85) | literature escape |
{k}SLfNTiAvL
|
Gag(77-85) | literature escape |
{k}SLYNTVATL
|
Gag(77-85) | literature escape |
SLfNTVATL
|
Gag(77-85) | escape documented in this paper; literature escape; susceptible form |
{k}SLfNTiATL
|
Gag(77-85) | literature escape |
{k}SLfNTVATL
|
Gag(77-85) | literature escape |
SLYNTiATL
|
Gag(77-85) | diminished HLA binding or increased off-rate; diminished response; escape documented in this paper; literature escape; susceptible form |
SLYNTiAvL
|
Gag(77-85) | diminished HLA binding or increased off-rate; escape documented in this paper; literature escape; susceptible form |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 transgenic mouse epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLhNaVAvL
|
Gag(77-85) | escape documented in this paper |
SLfNTVATL
|
Gag(77-85) | escape documented in this paper |
SLYNTiAvL
|
Gag(77-85) | susceptible form |
SLhNTVATL
|
Gag(77-85) | escape documented in this paper |
SLlNTVATL
|
Gag(77-85) | observed variant |
SLYNTVAvL
|
Gag(77-85) | observed variant |
SLYNTiATL
|
Gag(77-85) | observed variant |
SLsNTiATL
|
Gag(77-85) | observed variant |
SLfNTVAvL
|
Gag(77-85) | observed variant |
SLYNTVATL
|
Gag(77-85) | A*02:01 humanized mouse epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTiAvL
|
Gag(77-85) | literature escape |
SLfNTVATL
|
Gag(77-85) | literature escape |
SLYNTiATL
|
Gag(77-85) | literature escape |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTiATL
|
Gag(77-85) | escape documented in this paper; processing; susceptible form |
SvYNTVATL
|
Gag(77-85) | escape documented in this paper; processing; susceptible form |
SLYNlVATL
|
Gag(77-85) | escape documented in this paper; processing; susceptible form |
SLfNTVAvL
|
Gag(77-85) | escape documented in this paper; processing; susceptible form |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLfNTVATL
|
Gag(77-85) | susceptible form |
SLYNTiATL
|
Gag(77-85) | susceptible form |
SLfNTiATL
|
Gag(77-85) | susceptible form |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVVTL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVaTL
|
Gag(77-85) | susceptible form |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLfNTVATL
|
Gag(77-85) | escape documented in this paper; susceptible form |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
{l}SLYNTVAvL
|
Gag(77-85) | observed variant |
{l}SLYNTVATL
|
Gag(77-85) | susceptible form |
{m}SLYNTVATL
|
Gag(77-85) | observed variant |
SLYNaVAvL
|
Gag(77-85) | non-susceptible form |
{m}SLYNTVAvL
|
Gag(77-85) | observed variant |
{i}SLYNTVATL
|
Gag(77-85) | observed variant |
aLYNTVAvL
|
Gag(77-85) | observed variant |
aLfNTVATL
|
Gag(77-85) | observed variant |
SLYNiVATL
|
Gag(77-85) | observed variant |
{q}SLYNTVAvL
|
Gag(77-85) | observed variant |
{q}SLYNTVATL
|
Gag(77-85) | observed variant |
{v}SLYNTVATL
|
Gag(77-85) | observed variant |
SLYNcVATL
|
Gag(77-85) | observed variant |
{t}SLYNTVATL
|
Gag(77-85) | observed variant |
SLYNTiAsL
|
Gag(77-85) | observed variant |
SLYNsVAvL
|
Gag(77-85) | observed variant |
SLYNciATL
|
Gag(77-85) | observed variant |
aLYNTVATL
|
Gag(77-85) | observed variant |
SLYNTVAvL
|
Gag(77-85) | observed variant |
SLYNlVATL
|
Gag(77-85) | observed variant |
{t}SLYNTVAvL
|
Gag(77-85) | observed variant |
{v}SLYNTVAvL
|
Gag(77-85) | observed variant |
SLYNTiAvL
|
Gag(77-85) | observed variant |
{l}SLYNlVATL
|
Gag(77-85) | observed variant |
{n}SLYNTVAvL
|
Gag(77-85) | observed variant |
{f}SLYNTVATL
|
Gag(77-85) | observed variant |
SLYNTiATL
|
Gag(77-85) | observed variant |
SLYNTVAcL
|
Gag(77-85) | non-susceptible form |
{l}SLYNTVAcL
|
Gag(77-85) | observed variant |
{l}SLYNTVATL{w}
|
Gag(77-85) | observed variant |
{c}SLYNTVATL
|
Gag(77-85) | observed variant |
{k}SLYNTVATL
|
Gag(77-85) | observed variant |
SLYNcVAcL
|
Gag(77-85) | non-susceptible form |
SLYNTcAvL
|
Gag(77-85) | observed variant |
SLYNTVAsL
|
Gag(77-85) | observed variant |
SLfNTVATL
|
Gag(77-85) | observed variant |
SLYNlVAvL
|
Gag(77-85) | observed variant |
SLYNTVAaL
|
Gag(77-85) | observed variant |
{m}SLYNlVATL
|
Gag(77-85) | observed variant |
{v}SLYNlVATL
|
Gag(77-85) | observed variant |
{h}SLYNTVATL
|
Gag(77-85) | observed variant |
{a}SLYNTVATL
|
Gag(77-85) | observed variant |
SLYNTVATL{c}
|
Gag(77-85) | observed variant |
SLYNTVATL{f}
|
Gag(77-85) | observed variant |
{v}SLYNTVATL{w}
|
Gag(77-85) | observed variant |
{m}SLYNTVATL{w}
|
Gag(77-85) | observed variant |
{w}SLYNTVATL
|
Gag(77-85) | observed variant |
{s}SLYNTVATL
|
Gag(77-85) | observed variant |
{n}SLYNTVATL
|
Gag(77-85) | observed variant |
{a}aLYNTVATL
|
Gag(77-85) | observed variant |
{l}aLYNTVATL
|
Gag(77-85) | observed variant |
{l}SLYsTVATL
|
Gag(77-85) | observed variant |
{c}SLYNTVAvL
|
Gag(77-85) | observed variant |
{s}SLYNTVAvL
|
Gag(77-85) | observed variant |
{v}SLYNTVAsL
|
Gag(77-85) | observed variant |
{l}SLYNTVAaL
|
Gag(77-85) | observed variant |
{v}SLYNTVAaL
|
Gag(77-85) | observed variant |
SLYNTVAvL{w}
|
Gag(77-85) | observed variant |
SLYNTVAvL{s}
|
Gag(77-85) | observed variant |
SLYNTVAvL{r}
|
Gag(77-85) | observed variant |
SLYNTVATL{w}
|
Gag(77-85) | observed variant |
SLYNTVATm
|
Gag(77-85) | observed variant |
aLYNTVAaL
|
Gag(77-85) | observed variant |
aLYNTVAsL
|
Gag(77-85) | observed variant |
SLYNaVATL
|
Gag(77-85) | observed variant |
SLYNsVATL
|
Gag(77-85) | observed variant |
SLYNvVATL
|
Gag(77-85) | observed variant |
SLYNrVATL
|
Gag(77-85) | observed variant |
SLYNlVAsL
|
Gag(77-85) | observed variant |
SLYNvVAsL
|
Gag(77-85) | observed variant |
gLYNTVAvL
|
Gag(77-85) | observed variant |
cLYNTVAvL
|
Gag(77-85) | observed variant |
gLYNTVATL
|
Gag(77-85) | observed variant |
mLYNTVATL
|
Gag(77-85) | observed variant |
SLYmTVATL
|
Gag(77-85) | observed variant |
SLYrTVATL
|
Gag(77-85) | observed variant |
SLYgTVAvL
|
Gag(77-85) | observed variant |
SLYsTVAvL
|
Gag(77-85) | observed variant |
SLYcTVAvL
|
Gag(77-85) | observed variant |
SLYgTVAsL
|
Gag(77-85) | observed variant |
SLYgTVgTL
|
Gag(77-85) | observed variant |
SLYNTVgTL
|
Gag(77-85) | observed variant |
SLYNTVsTL
|
Gag(77-85) | observed variant |
SLYNTcATL
|
Gag(77-85) | observed variant |
SiYNTVATL
|
Gag(77-85) | observed variant |
StYNTVATL
|
Gag(77-85) | observed variant |
ScYNTVATL
|
Gag(77-85) | observed variant |
SvYNTVATL
|
Gag(77-85) | observed variant |
avYNTVATL
|
Gag(77-85) | observed variant |
vLYNTVATL
|
Gag(77-85) | observed variant |
tLYNTVATL
|
Gag(77-85) | observed variant |
rLYNTVATL
|
Gag(77-85) | observed variant |
wLYNTVATL
|
Gag(77-85) | observed variant |
qLYNTVATL
|
Gag(77-85) | observed variant |
SLYyTVATL
|
Gag(77-85) | observed variant |
SLYvTVATL
|
Gag(77-85) | observed variant |
SLYfTVATL
|
Gag(77-85) | observed variant |
SLYsTVATL
|
Gag(77-85) | observed variant |
SLYlTVATL
|
Gag(77-85) | observed variant |
SLYaTVATL
|
Gag(77-85) | observed variant |
SLYtTVATL
|
Gag(77-85) | observed variant |
SLYgaVATL
|
Gag(77-85) | observed variant |
SLYyTVAvL
|
Gag(77-85) | observed variant |
SLYslVATL
|
Gag(77-85) | observed variant |
SLYNvlATL
|
Gag(77-85) | observed variant |
SLYNTtATL
|
Gag(77-85) | observed variant |
SLYNTlATL
|
Gag(77-85) | observed variant |
SLYNTVgvL
|
Gag(77-85) | observed variant |
SLYNTVAiL
|
Gag(77-85) | observed variant |
SLrNTVATL
|
Gag(77-85) | observed variant |
SLvNTVATL
|
Gag(77-85) | observed variant |
SLwNTVATL
|
Gag(77-85) | observed variant |
SLYNTVATv
|
Gag(77-85) | observed variant |
SLYNTVATi
|
Gag(77-85) | observed variant |
{y}SLYNTVATL
|
Gag(77-85) | observed variant |
SLYNTVATL{l}
|
Gag(77-85) | observed variant |
{l}SLYNvVATL
|
Gag(77-85) | observed variant |
{c}SLYNlVATL
|
Gag(77-85) | observed variant |
{c}SLYNvVATL
|
Gag(77-85) | observed variant |
{g}SLYNTVATL
|
Gag(77-85) | observed variant |
{e}SLYNTVATL
|
Gag(77-85) | observed variant |
{l}gLYNTVATL
|
Gag(77-85) | observed variant |
SLYNTVAvL{l}
|
Gag(77-85) | observed variant |
{k}SvYNTVATL
|
Gag(77-85) | observed variant |
{v}gLYNTVATL
|
Gag(77-85) | observed variant |
SLYNTVATL{a}
|
Gag(77-85) | observed variant |
{v}SLYaTVATL
|
Gag(77-85) | observed variant |
SLYgTVATL{m}
|
Gag(77-85) | observed variant |
SLYNTVAvL{a}
|
Gag(77-85) | observed variant |
SLYgTVATL{a}
|
Gag(77-85) | observed variant |
SLYNvVATL{w}
|
Gag(77-85) | observed variant |
aLYNTVATL{l}
|
Gag(77-85) | observed variant |
SLYNTVAcL{l}
|
Gag(77-85) | observed variant |
SLYNTVATL{m}
|
Gag(77-85) | observed variant |
{a}SLYNTVAvL
|
Gag(77-85) | observed variant |
{v}SLYNTVAcL
|
Gag(77-85) | observed variant |
SLYcTVATL
|
Gag(77-85) | non-susceptible form |
SLYgTVATL
|
Gag(77-85) | observed variant |
SLYhTVATL
|
Gag(77-85) | observed variant |
SLYhlVATL
|
Gag(77-85) | observed variant |
SLYNmVATL
|
Gag(77-85) | observed variant |
SLYNTVvTL
|
Gag(77-85) | observed variant |
cLYNTVATL
|
Gag(77-85) | observed variant |
{v}SLYNTVATL{l}
|
Gag(77-85) | observed variant |
{c}aLYNTVATL
|
Gag(77-85) | observed variant |
{q}aLYNTVATL
|
Gag(77-85) | observed variant |
{a}SLYNTVATv
|
Gag(77-85) | observed variant |
SLYNTVAvL{m}
|
Gag(77-85) | observed variant |
{v}SvYNTVATL
|
Gag(77-85) | observed variant |
SLYgTVcTL
|
Gag(77-85) | observed variant |
SLYNTVATL{r}
|
Gag(77-85) | observed variant |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLfNTVATL
|
Gag(77-85) | diminished HLA binding or increased off-rate |
SLYNTVAvL
|
Gag(77-85) | diminished HLA binding or increased off-rate |
SLYNTiATL
|
Gag(77-85) | diminished HLA binding or increased off-rate |
SLfNTiAvL
|
Gag(77-85) | diminished HLA binding or increased off-rate; literature escape |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLFNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLFNTVAAL
|
Gag(77-85) | diminished response |
SLFNTVATP
|
Gag(77-85) | diminished response |
SLFSTVATL
|
Gag(77-85) | observed variant |
SLFNTIATL
|
Gag(77-85) | susceptible form |
SLYNTVATL
|
Gag(77-85) | susceptible form |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 humanized mouse epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLfNTVATL
|
Gag(77-85) | subtype-specific susceptible form |
SLYNTiaTL
|
Gag(77-85) | subtype-specific susceptible form |
SLYNIiAvL
|
Gag(77-85) | subtype-specific susceptible form |
SLYNTVAvL
|
Gag(77-85) | subtype-specific susceptible form |
SLfNTiATL
|
Gag(77-85) | subtype-specific susceptible form |
SLfNTiAvL
|
Gag(77-85) | subtype-specific susceptible form |
SLfNTVAvL
|
Gag(77-85) | subtype-specific susceptible form |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTIATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTIAvL
|
Gag(77-85) | susceptible form |
SLYNTvATL
|
Gag(77-85) | susceptible form |
SLYNTVATL
|
Gag(77-85) | A*02:01 human, transgenic mouse epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 transgenic mouse epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 humanized mouse epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 mouse epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 mouse epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 epitope |
SLfNTVATL
|
Gag(77-85) | susceptible form |
SLYNTiATL
|
Gag(77-85) | susceptible form |
SLYNTVAvL
|
Gag(77-85) | susceptible form |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 mouse epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLFNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLyNTVATL
|
Gag(77-85) | subtype-specific non-susceptible form |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLfNTiATL
|
Gag(77-85) | subtype-specific non-susceptible form; subtype-specific susceptible form |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 mouse epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human, transgenic mouse epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLFNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVAAL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLfNaiAvL
|
Gag(77-85) | subtype-specific non-susceptible form |
SLfNTVATL
|
Gag(77-85) | subtype-specific non-susceptible form |
SLYNTiATL
|
Gag(77-85) | subtype-specific susceptible form |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLfNTVATL
|
Gag(77-85) | diminished HLA binding or increased off-rate; escape documented in this paper |
SLfNTVAvL
|
Gag(77-85) | escape documented in this paper; TCR related mutation |
SLYNTVvTL
|
Gag(77-85) | inferred escape |
SLfNTiATL
|
Gag(77-85) | inferred escape |
SLYNTiAvL
|
Gag(77-85) | escape documented in this paper; TCR related mutation |
SLhNTVAvL
|
Gag(77-85) | diminished HLA binding or increased off-rate; escape documented in this paper |
SLYNTVAvL
|
Gag(77-85) | diminished HLA binding or increased off-rate; escape documented in this paper |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:01, A*02:14 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:02 human epitope |
SLYNTVATL
|
Gag(77-85) | A*02:02, A2 human epitope |
SLfNTVATL
|
Gag(77-85) | susceptible form |
SLYNTVATL
|
Gag(77-85) | A*02:05 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human, transgenic mouse epitope |
SLfNTVATL
|
Gag(77-85) | susceptible form |
SLYNlVATL
|
Gag(77-85) | susceptible form |
SLfNlVATL
|
Gag(77-85) | susceptible form |
SiYNlVATL
|
Gag(77-85) | susceptible form |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLFNTVATL
|
Gag(77-85) | A2 human epitope |
SLyNTVATL
|
Gag(77-85) | susceptible form |
SLYNTIATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLfNTVATL
|
Gag(77-85) | escape documented in this paper |
SLYNTVAvL
|
Gag(77-85) | escape documented in this paper |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 mouse epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human, transgenic mouse epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTAVTL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLfNTVATL
|
Gag(77-85) | escape documented in this paper; susceptible form; TCR related mutation |
SLYNTiATL
|
Gag(77-85) | escape documented in this paper |
SLYNTiAvL
|
Gag(77-85) | escape documented in this paper; non-susceptible form; susceptible form; TCR related mutation |
SLfNTiATL
|
Gag(77-85) | escape documented in this paper; non-susceptible form; susceptible form; TCR related mutation |
SLYNlVAvL
|
Gag(77-85) | escape documented in this paper; non-susceptible form; TCR related mutation |
SLYNTVAaL
|
Gag(77-85) | observed variant |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLfNTVcvi
|
Gag(77-85) | diminished response; escape documented in this paper; subtype-specific non-susceptible form; TCR related mutation |
SLfNTVATL
|
Gag(77-85) | diminished response; escape documented in this paper; subtype-specific non-susceptible form; TCR related mutation |
SLfNaVATL
|
Gag(77-85) | diminished response; escape documented in this paper; subtype-specific non-susceptible form; TCR related mutation |
SLaNTVATL
|
Gag(77-85) | diminished response; escape documented in this paper; TCR related mutation |
SLYaTVATL
|
Gag(77-85) | diminished response; escape documented in this paper; TCR related mutation |
SLYNaVATL
|
Gag(77-85) | diminished response; escape documented in this paper; TCR related mutation |
SLYNTaATL
|
Gag(77-85) | susceptible form |
SLYNTVAaL
|
Gag(77-85) | diminished response; escape documented in this paper; TCR related mutation |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLFNTVATL
|
Gag(77-85) | A2 human epitope |
SLyNTVATL
|
Gag(77-85) | escape documented in this paper |
SLyNaVATL
|
Gag(77-85) | escape documented in this paper |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 transgenic mouse epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLfNTVATL
|
Gag(77-85) | observed variant |
SLYNTiATL
|
Gag(77-85) | observed variant |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLfNTiATL
|
Gag(77-85) | escape documented in this paper |
SLfNTiAaL
|
Gag(77-85) | observed variant |
SLfNTVAvL
|
Gag(77-85) | escape documented in this paper |
SLfsTVAvL
|
Gag(77-85) | observed variant |
SLfNTVAvp
|
Gag(77-85) | observed variant |
SLfNTiAvL
|
Gag(77-85) | observed variant |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLfNTVATL
|
Gag(77-85) | susceptible form |
SLYNTiATL
|
Gag(77-85) | susceptible form |
SLYNTVAvL
|
Gag(77-85) | susceptible form |
SLYNaVATL
|
Gag(77-85) | susceptible form |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTiATL
|
Gag(77-85) | susceptible form |
SLYNTiAvL
|
Gag(77-85) | susceptible form |
SLYNTVAvL
|
Gag(77-85) | susceptible form |
SLfNTVATL
|
Gag(77-85) | susceptible form |
SLfNTiAvL
|
Gag(77-85) | susceptible form |
SLfNTVAvL
|
Gag(77-85) | susceptible form |
SLfNTiATL
|
Gag(77-85) | susceptible form |
SLYNsVATL
|
Gag(77-85) | susceptible form |
SLYqTVATL
|
Gag(77-85) | susceptible form |
SLYlTVATL
|
Gag(77-85) | susceptible form |
aLYNTVATL
|
Gag(77-85) | susceptible form |
SLaNTVATL
|
Gag(77-85) | non-susceptible form |
SLYaTVATL
|
Gag(77-85) | non-susceptible form |
SLYNTaATL
|
Gag(77-85) | diminished response |
SLYNTVAaL
|
Gag(77-85) | diminished response |
aLYNTaAaL
|
Gag(77-85) | non-susceptible form |
SLYNvVATL
|
Gag(77-85) | non-susceptible form |
SLYNlVAvL
|
Gag(77-85) | escape documented in this paper; TCR related mutation |
SLYNlVAvL
|
Gag(77-85) | escape documented in this paper; TCR related mutation |
SLYNaVATL
|
Gag(77-85) | escape documented in this paper; TCR related mutation |
SLYNaiATL
|
Gag(77-85) | escape documented in this paper; TCR related mutation |
SLYNlVAvL
|
Gag(77-85) | escape documented in this paper; TCR related mutation |
SLYNTVATL
|
Gag(77-85) | A2 human, mouse epitope |
SLYNTVAaL
|
Gag(77-85) | susceptible form |
lLYNTVATL
|
Gag(77-85) | susceptible form |
SLYNTVAsL
|
Gag(77-85) | susceptible form |
SLYNTpATL
|
Gag(77-85) | susceptible form |
lLYNTVAaL
|
Gag(77-85) | susceptible form |
lLYNTVAsL
|
Gag(77-85) | susceptible form |
lLYNTVlTL
|
Gag(77-85) | susceptible form |
SLYNTsAaL
|
Gag(77-85) | susceptible form |
lLYNTpATL
|
Gag(77-85) | susceptible form |
SLYNTpAaL
|
Gag(77-85) | susceptible form |
SLYNTpAsL
|
Gag(77-85) | susceptible form |
SLhNwslaL
|
Gag(77-85) | susceptible form |
SLwNwplaL
|
Gag(77-85) | susceptible form |
SLwNwplsL
|
Gag(77-85) | susceptible form |
SLhNwplaL
|
Gag(77-85) | susceptible form |
SLhNwplsL
|
Gag(77-85) | susceptible form |
lLwNTslaL
|
Gag(77-85) | susceptible form |
lLwNwslaL
|
Gag(77-85) | susceptible form |
lLwNwslsL
|
Gag(77-85) | susceptible form |
lLwNwplaL
|
Gag(77-85) | susceptible form |
lLhNwslaL
|
Gag(77-85) | susceptible form |
lLhNwplsL
|
Gag(77-85) | susceptible form |
SLfNTVATL
|
Gag(77-85) | escape documented in this paper; susceptible form |
SLfNTVAvL
|
Gag(77-85) | diminished response; escape documented in this paper |
SLfNTiAvL
|
Gag(77-85) | escape documented in this paper; susceptible form |
SLYNTiATL
|
Gag(77-85) | diminished response; susceptible form |
SLYNTiAvL
|
Gag(77-85) | diminished response; susceptible form |
SvYNTVATL
|
Gag(77-85) | diminished response; susceptible form |
SLYNTVAvL
|
Gag(77-85) | diminished response; susceptible form |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTiATL
|
Gag(77-85) | non-susceptible form; susceptible form |
SLYNTVAvL
|
Gag(77-85) | observed variant |
SLfNTVAvL
|
Gag(77-85) | escape documented in this paper |
SLfNTVATL
|
Gag(77-85) | diminished HLA binding or increased off-rate; susceptible form |
SLfNTiATL
|
Gag(77-85) | diminished response |
SLfNTiAvL
|
Gag(77-85) | escape documented in this paper; TCR related mutation |
SLhNaVAvL
|
Gag(77-85) | susceptible form |
SLYNTiAvL
|
Gag(77-85) | diminished response |
SLYNTiAiL
|
Gag(77-85) | observed variant |
SLfNTVATv
|
Gag(77-85) | susceptible form |
SLYNaVATL
|
Gag(77-85) | susceptible form |
SLYNlVAvL
|
Gag(77-85) | diminished HLA binding or increased off-rate |
SLYNTVAif
|
Gag(77-85) | diminished HLA binding or increased off-rate |
SLfNaVATL
|
Gag(77-85) | reversion; susceptible form |
SLfNaVAvL
|
Gag(77-85) | susceptible form |
SLfNmVATL
|
Gag(77-85) | susceptible form |
SLYNTVsTL
|
Gag(77-85) | susceptible form |
SLYNTitvL
|
Gag(77-85) | susceptible form |
SLYNTisvL
|
Gag(77-85) | susceptible form |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLFNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVAVL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVAvL
|
Gag(77-85) | diminished response |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLfNTVATL
|
Gag(77-85) | observed variant |
SLYNTVAvL
|
Gag(77-85) | observed variant |
SLYNTVATi
|
Gag(77-85) | observed variant |
SLfNTVATi
|
Gag(77-85) | observed variant |
SLnNaiAvL
|
Gag(77-85) | observed variant |
SvYNTVATL
|
Gag(77-85) | observed variant |
SLFNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 transgenic mouse epitope |
SLYNTVATL
|
Gag(77-85) | A2 humanized mouse epitope |
SLYNTVATL
|
Gag(77-85) | A2 epitope |
SLFNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLfNTVATL
|
Gag(77-85) | subtype-specific susceptible form |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 transgenic mouse epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLfNTVATL
|
Gag(77-85) | observed variant |
SLfNTVAvL
|
Gag(77-85) | diminished HLA binding or increased off-rate |
SLsNTVATL
|
Gag(77-85) | diminished HLA binding or increased off-rate |
SsfNTVATL
|
Gag(77-85) | observed variant |
SLlNTVATL
|
Gag(77-85) | diminished HLA binding or increased off-rate |
SLcNTVATL
|
Gag(77-85) | diminished HLA binding or increased off-rate |
SLYNTiATL
|
Gag(77-85) | observed variant |
SLfNaVATL
|
Gag(77-85) | diminished HLA binding or increased off-rate |
SLfNTiAvL
|
Gag(77-85) | diminished HLA binding or increased off-rate |
SLfNTiATL
|
Gag(77-85) | observed variant |
SLYNTiAvL
|
Gag(77-85) | diminished HLA binding or increased off-rate |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLfNTVATL
|
Gag(77-85) | observed variant |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVAvL
|
Gag(77-85) | susceptible form |
SLfNTVAvL
|
Gag(77-85) | susceptible form |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2 human epitope |
SLYNTVATL
|
Gag(77-85) | A2, A68 human epitope |
SLfNTiATL
|
Gag(77-85) | diminished response |
SLYNTVATL
|
Gag(77-85) | B*57 human epitope |
SLYNTVATL
|
Gag(77-85) | C*14 human epitope |
SLYNTVATL
|
Gag(77-85) | H-2d human, mouse epitope |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLFNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATL
|
Gag(77-85) | epitope |
SLYNTVAvL
|
Gag(77-85) | susceptible form |
SLYNTiATL
|
Gag(77-85) | escape documented in this paper; susceptible form |
SLYNTiAvL
|
Gag(77-85) | susceptible form |
SLYNTVATL
|
Gag(77-85) | human epitope |
pLYNTVATL
|
Gag(77-85) | HLA association; TCR related mutation |
SLfNTVATL
|
Gag(77-85) | HLA association; TCR related mutation |
SLYNTiATL
|
Gag(77-85) | HLA association; TCR related mutation |
SLfNTVAvL
|
Gag(77-85) | HLA association; TCR related mutation |
SLfNaVAvL
|
Gag(77-85) | HLA association; TCR related mutation |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATL
|
Gag(77-85) | human epitope |
SLYNTVATLY
|
Gag(77-86) | A*02 human epitope |
SLYNTVATLY
|
Gag(77-86) | A*02 human epitope |
SLYNTVAvLY
|
Gag(77-86) | diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form |
SLYNTiATLY
|
Gag(77-86) | diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form |
SLYNTiAvLY
|
Gag(77-86) | diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form |
SLfNTVATLY
|
Gag(77-86) | diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form |
SLfNTiAvLY
|
Gag(77-86) | diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form |
SLfNTVAvLY
|
Gag(77-86) | diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form |
SLfNTiATLY
|
Gag(77-86) | diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form |
SLYNTVATLY
|
Gag(77-86) | A*02:01 human epitope |
SLYNTVATLY
|
Gag(77-86) | A2 human epitope |
SLYNTVATLY
|
Gag(77-86) | A2 human epitope |
SLFNTVATLY
|
Gag(77-86) | human epitope |
SLYNTVATLY
|
Gag(77-86) | human epitope |
SLYNTVATLY
|
Gag(77-86) | human epitope |
SLYNIVATLWCVH
|
Gag(77-89) | human epitope |
SLYNTVATLYCVHQR
|
Gag(77-91) | A*02:01, A*30:02 human epitope |
SLfNTVATLYCVHQR
|
Gag(77-91) | susceptible form |
SLYNTVATLYCVHQR
|
Gag(77-91) | A2, B44, B60 human epitope |
SLYNTVATLYCVHQR
|
Gag(77-91) | H-2d transgenic mouse epitope |
SLYNTVATLYCVHQR
|
Gag(77-91) | mouse epitope |
SLYNTVATLYCVHQR
|
Gag(77-91) | human epitope |
SLYNTVATLYCVHQRIEV
|
Gag(77-94) | human epitope |
SLYNTVATLYCVHQRIEV
|
Gag(77-94) | human epitope |
LYNTVATL
|
Gag(78-85) | A*02 human epitope |
LYNTVATL
|
Gag(78-85) | A24 human epitope |
LYNTVATL
|
Gag(78-85) | C*14 human epitope |
LYNTVAVL
|
Gag(78-85) | C*14 human epitope |
LYNTVATL
|
Gag(78-85) | C*14 human epitope |
LYNTVATL
|
Gag(78-85) | C*14 human epitope |
LYNTVATL
|
Gag(78-85) | C*14 human epitope |
LYNTVATL
|
Gag(78-85) | C*14:02 human epitope |
LYNTVATL
|
Gag(78-85) | C*14:02, C*14:03 human epitope |
LYNTVATL
|
Gag(78-85) | H-2d mouse epitope |
LYNTVATL
|
Gag(78-85) | human epitope |
LYNTVATLY
|
Gag(78-86) | A*02 human epitope |
LYNTVATLY
|
Gag(78-86) | A*29 human epitope |
LYNTVATLY
|
Gag(78-86) | A*29 human epitope |
LYNTVATLY
|
Gag(78-86) | A*29 human epitope |
LYNTVAVLY
|
Gag(78-86) | A*29 human epitope |
LYNTiAVLY
|
Gag(78-86) | observed variant |
LfNTiAVLY
|
Gag(78-86) | observed variant |
LfNTVAVLY
|
Gag(78-86) | observed variant |
LYNTVATLY
|
Gag(78-86) | A*29, B*44 epitope |
LYNTVATLY
|
Gag(78-86) | A29 human epitope |
LYNTVATLY
|
Gag(78-86) | A*29:02 human epitope |
LFNTVATLY
|
Gag(78-86) | A*29:02 human epitope |
LYNTVATLY
|
Gag(78-86) | A*29:02 human epitope |
LYNTIATLY
|
Gag(78-86) | A*29:02 human epitope |
LYNTVATLY
|
Gag(78-86) | A*29:02, B*44:03 human epitope |
LYNTVATLY
|
Gag(78-86) | A*29:02, B*44:03 human epitope |
LYNTVATLY
|
Gag(78-86) | A*30 human epitope |
LYNTVATLY
|
Gag(78-86) | B*44:03 human epitope |
LYNTVATLY
|
Gag(78-86) | B*81 human epitope |
LYNTVATLY
|
Gag(78-86) | C*14 human epitope |
LYNTVATLY
|
Gag(78-86) | human epitope |
LFNTVATLY
|
Gag(78-86) | human epitope |
LyNTVATLY
|
Gag(78-86) | observed variant |
LYNTVATLY
|
Gag(78-86) | human epitope |
LYNTVATLY
|
Gag(78-86) | human epitope |
LFNTVATLYCV
|
Gag(78-88) | A*02 human epitope |
LYNTVATLYCVHQRI
|
Gag(78-92) | human epitope |
YNIVATLWCVHQ
|
Gag(79-90) | human epitope |
YNtVATLWCVHQ
|
Gag(79-90) | subtype-specific susceptible form |
YNTVATLYCVHQRI
|
Gag(79-92) | human epitope |